MCE products for research use only. We do not sell to patients.

Zymosan A

MCE China：Zymosan A

Brand：MedChemExpress (MCE)

Cat. No.HY-W250113

CAS：58856-93-2

Synonyms：Zymosan A from Saccharomyces cerevisiae

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury.

In Vivo：Dimethylnitrosamine pharmacokinetics in beagles shows that after intravenous injection, the concentration of Dimethylnitrosamine declines in a biphasic manner, with a mean distribution half-life of 19 minutes and a mean elimination half-life of 73 minutes. At low doses (0.5 and 1.0 mg/kg), the elimination rate of Dimethylnitrosamine is proportional to its blood concentration, but at high doses (5.0 mg/kg), metabolism becomes saturated. The mean systemic clearance of Dimethylnitrosamine is 43.3 mL/min/kg, the volume of distribution at steady state is 1.9 L/kg, and the mean residence time is 45 minutes. The oral bioavailability is as high as 93%.Dimethylnitrosamine can be used to create liver tumor models in animals[3][4]. .f12{ font-size: 12px; } .fwb{ font-weight: bold; } .lh22{ line-height: 22px;; } .lh23 { line-height: 23px; } .pl13{ padding-left: 13px;; } .part { margin-top: 18px; } .mold-first-tit { width: 100%; height: 44px; line-height: 44px; background: #F9F7FB; border-bottom: 1px solid #EBE4F6; padding-left: 16px; box-sizing: border-box; margin-bottom: 17px; } .mold-second-tit:before { content:; width: 6px; height: 6px; display: inline-block; border-radius: 50%; background: rgba(255,102,0,0.4); margin-right: 12px; position: relative; top: -3px; } .lft-border { border-left: 1px dotted #EBE4F6; padding-right: 12px; margin-left: 3px; box-sizing: border-box; padding-bottom: 12px; } /* .part .dec:last-child { border-bottom: 0; } */ .dec { margin: 10px 15px 0; padding-bottom: 10px; border-bottom: 1px dashed #EBE4F6; } .btm-border { border-left: 1px dashed #EBE4F6; } .text-bg { margin-top: 10px; background: #FFFBF1; padding: 14px; border-bottom: 0; position: relative; } .text-note-bg { margin-top: 10px; background: #FFFDF7; padding: 12px; border-bottom: 0; position: relative; } .text-note { width: 51px; height: 20px; line-height: 20px; background: #FFE2AA; text-align: center; border-radius: 0 0 8px 0; position: absolute; top: 0; left: 0; } .text-note-dec { margin-top: 15px;; } Induction of peritonitis[2] Background Zymosan A can mediate the release of pro-inflammatory cytokines including IL-1β, TNF-α, and HMGB1, inducing an inflammatory response leading to peritonitis. Specific Mmodeling Methods Mice: C57BL/6 • male • 3-7 months oldAdministration: 100 or 500 mg/kg • i.p. Note (1) ChAT-eGFP mice were randomly divided into two groups, and baseline rectal temperature and electrocardiogram (ECG) were measured in each group before injection.(2) Preparation of Zymosan A Suspension: Weigh Zymosan A and sterilise for 30 minutes with UV light, add sterile filtered saline and vortex thoroughly, store at room temperature overnight and vortex again before use to ensure thorough mixing.(3) Rectal temperature and ECG were recorded hourly 4 and 24 hours after Zymosan A injection, respectively. Modeling Indicators Phenotypic observation: Hypothermia; cardiac insufficiency, including increased variability of baseline heart rate (HR), moderate slowing of ventricular conduction, and decreased cardiac contractility; and bacterial translocation into the peritoneal cavity and bloodstream. Correlated Product(s): / Opposite Product(s): /

Hot selling product：6-Aminocaproic acid  | 2'-Acetylacteoside  | E-7386  | Fluorescein-5-thiosemicarbazide  | TY-51469  | Glyceraldehyde phosphate dehydrogenase  | Chlorambucil  | 3,3'-Diindolylmethane  | Cilnidipine  | Alagebrium chloride

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Du J, et al. Zymosan-A promotes the regeneration of intestinal stem cells by upregulating ASCL2. Cell Death Dis. 2022 Oct 20;13(10):884.  [Content Brief]

[2]. Monroe LL, et al. Zymosan-Induced Peritonitis: Effects on Cardiac Function, Temperature Regulation, Translocation of Bacteria, and Role of Dectin-1. Shock. 2016 Dec;46(6):723-730.  [Content Brief]